Scarica l'app Stockscreener
64.93
3.39%
2.13
Dopo l'orario di chiusura:
63.64
-1.29
-1.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$62.80
Aprire:
$62.79
Volume 24 ore:
772.42K
Relative Volume:
0.80
Capitalizzazione di mercato:
$1.23B
Reddito:
$90.12M
Utile/perdita netta:
$-276.06M
Rapporto P/E:
-44.47
EPS:
-1.46
Flusso di cassa netto:
$-193.47M
1 W Prestazione:
+8.04%
1M Prestazione:
+14.11%
6M Prestazione:
+8,062%
1 anno Prestazione:
+5,356%
Intervallo 1D:
$61.50
$66.92
Intervallo di 1 settimana:
$59.01
$66.92
Portata 52W:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Confronta NKTR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
64.93 | 1.19B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Using economic indicators to assess Nektar Therapeutics potential2025 Year in Review & Daily Momentum Trading Reports - newser.com
Will Nektar Therapeutics stock benefit from AI adoptionJuly 2025 Rallies & Real-Time Market Trend Scan - newser.com
Moody Aldrich Partners LLC Invests $1.17 Million in Nektar Therapeutics $NKTR - MarketBeat
Will Nektar Therapeutics continue its uptrend2025 Analyst Calls & AI Driven Price Predictions - newser.com
Nektar Therapeutics (NKTR): Valuation Reset as REZOLVE-AD Phase 2b Data and Analyst Optimism Drive Investor Interest - simplywall.st
Why Nektar Therapeutics stock remains undervaluedMarket Weekly Review & Daily Growth Stock Investment Tips - newser.com
Is Nektar Therapeutics (ITH0) stock undervalued at current priceQuarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com
Is Nektar Therapeutics trending in predictive chart models2025 Valuation Update & Community Supported Trade Ideas - newser.com
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 1-Year HighShould You Buy? - MarketBeat
Is Nektar Therapeutics (ITH0) stock a top dividend aristocrat candidateJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
Is Nektar Therapeutics stock a good choice for value investorsJuly 2025 Snapshot & Advanced Swing Trade Entry Plans - newser.com
Nektar Therapeutics stock hits 52-week high at 65.97 USD By Investing.com - Investing.com Australia
Can Nektar Therapeutics (ITH0) stock sustain free cash flowQuarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
Nektar Therapeutics (NKTR) Is Up 8.0% After Late-Breaking Phase 2b Rezpegaldesleukin Data Announcement - simplywall.st
What margin trends mean for Nektar Therapeutics stockTrade Entry Summary & Free Daily Entry Point Trade Alerts - newser.com
Nektar Therapeutics stock hits 52-week high at 65.97 USD - Investing.com
Best data tools to analyze Nektar Therapeutics stock2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Nektar Therapeutics (NKTR): Taking a Fresh Look at Valuation After Recent Share Price Rebound - Yahoo Finance
Can volume confirm reversal in Nektar TherapeuticsJuly 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Pattern recognition hints at Nektar Therapeutics upsideRecession Risk & Real-Time Market Trend Scan - newser.com
Nektar (NASDAQ: NKTR) to Webcast Jefferies London Event Nov. 20 with 30-day Replay - Stock Titan
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - sharewise.com
Nektar Therapeutics $NKTR Holdings Trimmed by Deuterium Capital Management LLC - MarketBeat
Why retail investors pile into Nektar Therapeutics stockPortfolio Return Report & Precise Trade Entry Recommendations - newser.com
Can Nektar Therapeutics stock resist market sell offsJuly 2025 Movers & Weekly High Return Opportunities - newser.com
Nektar Therapeutics (NKTR) to Release Earnings on Thursday - MarketBeat
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets - BioSpace
Published on: 2025-10-28 19:46:28 - Fundação Cultural do Pará
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):